The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal disease a treatment option that does not require incisions. Epioxa, ...

Please provide your email address to receive an email when new articles are posted on . Glaukos submitted a new drug application to the FDA for Epioxa, an epithelium-on corneal cross-linking iLink ...

In vitro test methods that use human corneal epithelial cells to evaluate the eye irritation potency of chemical substances do not use human corneal epithelium because it has been difficult to ...

Several studies conducted over the last decade have concluded that dry eye disease (DED) affects up to 50% of the U.S. population, creating a liability for the nation's health care system that is ...

This study identifies mechanisms of epithelial growth post-SMILE surgery and suggests preventive and treatment measures, including subflap debris removal, to address corneal epithelial ingrowth.

Also known as epithelial basement membrane dystrophy, map-dot-fingerprint dystrophy gets its name from the unusual appearance of the cornea during an eye examination.Map-dot-fingerprint dystrophy, ...

Please provide your email address to receive an email when new articles are posted on . Remarkable advances have occurred in corneal surgery in the past 10 years. These advances include simpler ...

Heidelberg Engineering, a global leader in ophthalmic imaging and healthcare data solutions, is pleased to announce FDA clearance of the Epithelial Thickness Module, available exclusively through the ...

Transplanted autologous corneal stem cells successfully repaired corneal injuries in patients. Over 90% of patients achieved complete or partial success. The procedure proved safe with no serious ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal ...